ArticleAdvances in therapy2026
Intraoperative Transcutaneous Electrical Acupoint Stimulation Attenuates Postoperative Mechanical Pain Sensitization and Visceral Pain After Elective Cesarean Delivery: A Randomized Controlled Trial.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPostoperative pain after cesarean delivery remains prevalent despite multimodal analgesia. This randomized controlled trial evaluated whether continuous intraoperative transcutaneous electrical acupoint stimulation (TEAS) attenuates postoperative mechanical pain sensitization and improves clinical pain outcomes.
methodsEighty parturients undergoing elective cesarean delivery under neuraxial anesthesia were randomized 1:1 to TEAS (PC6 and LI4; from 30 min before incision until 10 min after closure) or sham control. The primary outcome was mechanical pain sensitization, quantified by the 30-min postoperative-to-baseline pressure pain threshold (PPT) ratio. Secondary outcomes included PPT and pain tolerance threshold (PTO) at 30 min and 24 h, threshold change ratios, postoperative pain scores, patient-controlled intravenous analgesia (PCIA) use, adverse events, and hospital stay.
resultsSeventy-nine participants were analyzed. TEAS significantly increased the 30-min PPT ratio compared with control (mean difference 0.208, 95% CI 0.057-0.359; P = 0.008). PPT and PTO remained higher in the TEAS group at 24 h, and all four threshold change ratios favored TEAS (all P < 0.05). Clinically, TEAS reduced uterine cramping pain scores at 6 h and 24 h and lowered the incidence of severe visceral pain (15.38% vs. 40.00%; in the multivariable model, the adjusted OR was 0.26 [95% CI 0.08-0.73; P = 0.005]). Hospital stay was shorter in the TEAS group (median 6.00 vs. 7.00 days; P = 0.010). No intervention-related adverse events were observed. Static and dynamic incisional pain outcomes and cumulative analgesic consumption did not differ significantly between groups.
conclusionContinuous intraoperative TEAS was associated with attenuated postoperative mechanical pain sensitization and reduced visceral pain burden after elective cesarean delivery. Its effects were less evident for incision-related pain and opioid consumption. TEAS may serve as a safe, valuable non-pharmacological adjunct to multimodal post-cesarean analgesia. Apart from the primary outcome, secondary findings (including visceral pain, hospital stay, and threshold change ratios) were not adjusted for multiple comparisons and should be regarded as exploratory and hypothesis-generating. Graphical Abstract available for this article.
trial registrationChinese Clinical Trial Registry (ChiCTR2200058422).
Indexed as
Identifiers
42629532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.